Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors
A Patnaik, SP Kang, D Rasco, KP Papadopoulos… - Clinical cancer …, 2015 - AACR
Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor
activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with …
activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with …
Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors
A Patnaik, LS Rosen, SM Tolaney, AW Tolcher… - Cancer discovery, 2016 - AACR
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors
MH Taylor, EV Schmidt, C Dutcus, EM Pinheiro… - Future …, 2021 - Future Medicine
Tumor progression and immune evasion result from multiple oncogenic and
immunosuppressive signals within the tumor microenvironment. The combined blockade of …
immunosuppressive signals within the tumor microenvironment. The combined blockade of …
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
T Shimizu, AW Tolcher, KP Papadopoulos… - Clinical Cancer …, 2012 - AACR
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving
PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated …
PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated …
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
V Makker, D Rasco, NJ Vogelzang, MS Brose… - The Lancet …, 2019 - thelancet.com
Background Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and
other receptor tyrosine kinases. Pembrolizumab, an antibody targeting PD-1, has moderate …
other receptor tyrosine kinases. Pembrolizumab, an antibody targeting PD-1, has moderate …
[HTML][HTML] First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
BI Sikic, N Lakhani, A Patnaik, SA Shah… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients
With Advanced Cancers - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
With Advanced Cancers - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
[HTML][HTML] Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid …
PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …
[HTML][HTML] Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors
Purpose Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating
CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation prolongs the serum …
CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation prolongs the serum …
Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors
AW Tolcher, M Sznol, S Hu-Lieskovan… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor
activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb …
activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb …
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 …
Background Despite advances in the first-line treatment of metastatic renal cell carcinoma
(RCC), there is an unmet need for options to address disease progression during or after …
(RCC), there is an unmet need for options to address disease progression during or after …